Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate
-
poor substrate compared to 1-phosphatidyl-1D-myo-inositol 5-phosphate
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + dipalmitoyl-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + dipalmitoyl-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
663208, 721493, 721525, 723602, 737401, 737789, 738171, 758575, 758945, 759023, 759615 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
phosphorylation at the D-4 position
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
the enzyme may have an important role in synthesis of phosphatidylinositol bisphosphate in the endoplasmic reticulum
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
type II PIP kinases are physiological targets for protein kinase D phosphorylation. This modification is likely to regulate inositol lipid turnover by inhibition of these lipid kinases
-
-
?
additional information
?
-
-
the enzyme phosphorylated His-tagged ANAC078 protein at the C-terminus
-
-
?
additional information
?
-
-
although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduces rather than increases phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K, this reduction in PI-3,4,5-P3 levels results in decreased activation of the downstream protein kinase Akt/PKB, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, results in Akt activation, and this effect is partially reversed by PIP4K IIbeta, PIP4K IIbeta expression does not impair insulin-dependent association of PI3K with insulin receptor substrate 1 IRS1 but abbreviates Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
663208, 721493, 721525, 723602, 737401, 737789, 738171, 758575, 758945, 759023, 759615 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
the enzyme may have an important role in synthesis of phosphatidylinositol bisphosphate in the endoplasmic reticulum
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
type II PIP kinases are physiological targets for protein kinase D phosphorylation. This modification is likely to regulate inositol lipid turnover by inhibition of these lipid kinases
-
-
?
additional information
?
-
-
although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduces rather than increases phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K, this reduction in PI-3,4,5-P3 levels results in decreased activation of the downstream protein kinase Akt/PKB, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, results in Akt activation, and this effect is partially reversed by PIP4K IIbeta, PIP4K IIbeta expression does not impair insulin-dependent association of PI3K with insulin receptor substrate 1 IRS1 but abbreviates Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
-
-
(2E)-2-(3,4-dihydroxybenzoyl)-3-(4-hydroxy-3-iodo-5-methoxyphenyl)prop-2-enenitrile
-
-
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
-
(2Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)prop-2-enenitrile
-
-
(3E)-5-amino-3-[(2Z)-1-cyano-2-(3H-indol-3-ylidene)ethylidene]-2,3-dihydro-1H-pyrazole-4-carbonitrile
-
-
(3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
-
-
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
-
-
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
-
-
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
i.e. CVM-05-002, potent and selective inhibitor for isoform PI5P4Kalpha
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
2,4-diamino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
3-(trifluoromethyl)phenyl 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylate
-
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-(3-phenoxyphenyl)pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-methyl-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(benzylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(methylsulfanyl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(piperidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-hydroxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-methoxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(2,2-dimethylpropyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(tert-butylcarbamoyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[[(1-methyl-1H-pyrazol-5-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-N-(1,3-benzothiazol-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-(1-benzothiophen-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]-2-(3,4,4-trimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
-
5-[3-(methylsulfonyl)phenyl]-4-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]thieno[2,3-d]pyrimidine
-
-
AG-538
-
at a concentration of 0.02 mM, AG-538 induces an almost complete inhibition of isoform PI5P4Kalpha and inhibits isoforms PI5P4Ks beta and gamma by 90% and 85%, respectively
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
-
-
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
-
-
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
-
-
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
piperine
-
complete inhibition at 0.1 mM
tyrphostin
-
ATP-competitive inhibitors, i.e. tyrosine phosphorylation inhibitors, of isozyme PI5P4Kalpha
additional information
-
high-throughput inhibitor screening method, counterscreen assay and ATP competition assay, overview
-
NIH-12848
-
-
NIH-12848
-
very specific inhibitor
NIH-12848
-
full designation NCGC00012848-02, specific inhibitor of isoform PI5P4Kgamma, does not inhibit the alpha and beta PI5P4K isoforms at concentrations up to 0.1 mM; inhibitor of isoform PI5P4Kgamma only
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0026 - 0.0101
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
0.0019
(2Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)prop-2-enenitrile
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0021 - 0.0089
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0038
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00199 - 0.0356
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.002 - 0.0318
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
0.0035 - 0.0158
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0013 - 0.0062
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
0.00134 - 0.0099
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
0.0065 - 0.0205
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
0.0053 - 0.0336
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
0.0052 - 0.0298
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
0.0174 - 0.0304
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0193 - 0.0245
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0013 - 0.0063
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
0.0026
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0101
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0021
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0089
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00199
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0021
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0109
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0356
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.002
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0318
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0035
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0158
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0013
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0062
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.00134
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0099
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0065
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0205
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0053
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0336
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0052
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0298
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0174
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0304
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0193
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0245
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
0.0013
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0063
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
isoform PI5P4Kbeta, at pH 7.5 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.014
(2E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.002
(2E)-2-(3,4-dihydroxybenzoyl)-3-(4-hydroxy-3-iodo-5-methoxyphenyl)prop-2-enenitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.013
(3E)-5-amino-3-[(2Z)-1-cyano-2-(3H-indol-3-ylidene)ethylidene]-2,3-dihydro-1H-pyrazole-4-carbonitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.005
(3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.0061 - 0.027
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.0018 - 0.0086
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
0.035 - 0.05
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.011 - 0.05
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.026 - 0.05
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
0.0039 - 0.05
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
0.0014 - 0.0043
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
0.0088 - 0.05
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
0.028 - 0.05
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
0.011 - 0.05
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
0.00066 - 0.0027
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.021 - 0.05
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.00013 - 0.0019
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.011 - 0.05
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
0.00027 - 0.0017
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.004 - 0.025
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
0.03
2,4-diamino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
3-(trifluoromethyl)phenyl 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylate
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0054
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-(3-phenoxyphenyl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-methyl-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0081
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.013
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.025
4-amino-2-(benzylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-(methylsulfanyl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-(piperidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-hydroxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-2-methoxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.008
4-amino-2-[(2,2-dimethylpropyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-2-[(tert-butylcarbamoyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.0041
4-amino-2-[[(1-methyl-1H-pyrazol-5-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.025
4-amino-N-(1,3-benzothiazol-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.013
4-amino-N-(1-benzothiophen-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
at pH 7.4 and 26°C
0.03
4-amino-N-[3-(trifluoromethyl)phenyl]-2-(3,4,4-trimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.03
4-amino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
Homo sapiens
IC50 above 0.03 mM, at pH 7.4 and 26°C
0.014 - 0.045
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
0.009 - 0.025
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
0.0053 - 0.036
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
0.002 - 0.0094
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0089 - 0.015
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0037 - 0.043
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
0.0021 - 0.022
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0032 - 0.029
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
0.0038
SAR088
Homo sapiens
at pH 7.4 and 26°C
0.00095 - 0.0059
THZ-P1-2
0.001
tyrphostin
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.045
tyrphostin 23
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.02
tyrphostin 47
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.1
tyrphostin AG 1478
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.089
tyrphostin AG 490
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.089
tyrphostin AG 494
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.032
tyrphostin AG 537
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.055
tyrphostin AG 555
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.05
tyrphostin AG 698
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.018
tyrphostin AG 808
Homo sapiens
-
pH 7.4, 22°C, isozyme PI5P4Kalpha
0.0061
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.027
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0018
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0086
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.035
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.011
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.026
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0039
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0014
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0043
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0088
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.028
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.05
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.011
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00066
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0027
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.021
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00013
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0019
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.011
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.05
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
IC50 above 0.05 mM, isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.00027
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0017
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.004
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.025
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.014
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.045
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.009
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.025
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0053
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.036
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.002
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.0094
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0089
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.015
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0037
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.043
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0021
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.022
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.0032
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.4 and 25°C
0.029
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.4 and 25°C
0.001
NIH-12848
Mus musculus
-
at pH 7.5 and 30°C
0.001
NIH-12848
Mus musculus
-
at 22°C, pH not specified in the publication
0.00095
THZ-P1-2
Homo sapiens
-
isoform PI5P4Kalpha, at pH 7.5 and 37°C
0.0059
THZ-P1-2
Homo sapiens
-
isoform PI5P4Kbeta, at pH 7.5 and °C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
metabolism
-
the enzyme regulates plasma-membrane phosphatidylinositol 3,4,5-trisphosphate turnover and insulin signalling. The enzyme is required to limit phosphatidylinositol 3,4,5-trisphosphate levels during insulin receptor activation
evolution
-
PI5P4Kalpha is present in all vertebrates, and a few organisms are missing either beta or gamma. Several key structural differences between the three mammalian PI5P4Ks largely account for their different activities, e.g. a glycine-rich loop supposed to be involved with substrate interaction
evolution
-
two subfamilies of phosphatidylinositol 5-phosphate 4-kinase kinases produce 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate from independent pools of substrates. In addition, type I and II subfamilies of PIPK can localize in different subcellular compartments and are involved in the synthesis of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate in distinct sites within cell
evolution
-
two subfamilies of phosphatidylinositol 5-phosphate 4-kinases produce 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate from independent pools of substrates. In addition, type I and II subfamilies of PIPK can localize in different subcellular compartments and are involved in the synthesis of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate in distinct sites within cell
evolution
-
two subfamilies of phosphatidylinositol 5-phosphate 4-kinases produce 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate from independent pools of substrates. In addition, type I and II subfamilies of PIPK can localize in different subcellular compartments and are involved in the synthesis of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate in distinct sites within cell
-
malfunction
-
phosphatidylinositol-5-phosphate 4-kinase type II beta knockdown inhibits E-cadherin upregulation induced by the vitamin D3 metabolite 1alpha,25(OH)2D3, while phosphatidylinositol-5-phosphate 4-kinase type II alpha does not
malfunction
-
enzyme knockdown leads to severe morphological abnormalities, including midbody winding defects at 48 h post-fertilization
malfunction
-
isoform PI4Kgamma5 deficiency results in the serrated leaves and accelerated cell division at leaf margin due to the increased auxin level
malfunction
-
loss-of-function mutants in PIP4K show reduced body weight and prolonged larval development
malfunction
-
enzyme depletion enhances the spindle pole accumulation of mitotic centromere-associated kinesin, a microtubule-depolymerizing kinesin, and results in a less stable spindle pole-associated microtubule
malfunction
-
enzyme-deficient animals show enhanced insulin signaling-dependent phenotypes and are resistant to the metabolic consequences of a high-sugar diet
malfunction
-
flies lacking the enzyme show mislocalization of rhodopsin 1 on expanded endomembranes within the cell body. Enzyme loss is associated with increased clathrin-mediated endocytosis and an enlarged Rab5-positive compartment in cultured Drosophila cells
malfunction
-
long-Term loss of isoform PI5P4Kalpha by gene disruption results in compromised Akt phosphorylation
malfunction
-
mice lacking both enzyme isoforms in the liver have a defect in the ability to catabolize lipid droplets following a period of fasting. Enzyme loss of both isoforms results in lipid droplets accumulation and autophagy defects in MEF cells. Enzyme loss modifies expression of lysosomal and mTORC1 genes and alters metabolism as well as increases transcription factor EB nuclear translocation and activity
physiological function
-
greater type II alpha PIP kinase activity in the light-adapted rod outer segment membrane results from light-driven translocation of PIPKIIalpha from the rod inner segment to rod outer segment, and subsequent binding to the rod outer segment membrane, thus improving access of the kinase to its lipid substrates. Light-induced tyrosine phosphorylation of rod outer segment membrane proteins regulate the translocation, membrane binding and activation of type II alpha phosphatidylinositol-5-phosphate 4-kinase
physiological function
-
greater type II alpha PIP kinase activity in the light-adapted rod outer segment membrane results from light-driven translocation of PIPKIIalpha from the rod inner segment to rod outer segment, and subsequent binding to the rod outer segment membrane, thus improving access of the kinase to its lipid substrates. Light-induced tyrosine phosphorylation of rod outer segment membrane proteins regulate the translocation, membrane binding and activation of type II alpha phosphatidylinositol-5-phosphate 4-kinase
physiological function
-
isozyme PIP4Kalpha affects the ubiquitination of isozyme PIP4Kbeta by the SPOP-CUL3 complex. Isozyme PIP4Kbeta can modulate the nuclear localization of isozyme PIP4Kalpha, and isozyme PIP4Kalpha has a role in regulating isozyme PIP4Kbeta functions
physiological function
-
isozyme PIP4Kalpha affects the ubiquitination of isozyme PIP4Kbeta by the SPOP-CUL3 complex. Isozyme PIP4Kbeta can modulate the nuclear localization of isozyme PIP4Kalpha, and isozyme PIP4Kalpha has a role in regulating isozyme PIP4Kbeta functions
physiological function
-
the enzyme is required for vitamin D receptor-mediated E-cadherin induction in SW480-ADH cells expressing the vitamin D receptor. The enzyme is also involved in the suppression of the cell motility induced by 1alpha,25-dihydroxyvitamin D3, PIPKIIbeta inhibits the migratory activity of SW480-ADH cells. PIPKIIbeta-mediated phosphatidylinositol-4,5-bisphosphate signaling is important for E-cadherin upregulation and inhibition of cellular motility induced by vitamin D receptor activation. PIPKIIbeta but not PIPKIIalpha promotes E-cadherin upregulation in the presence of 1alpha,25(OH)2D3, overview
physiological function
-
isoform PI4Kgamma5 interacts with transcription factor ANAC078 to negatively regulate auxin synthesis and hence influences cell proliferation and leaf development
physiological function
-
the enzyme is part of piperine-mediated anti-inflammatory signaling mechanisms
physiological function
the enzyme isoform PIP5K2B is linked to the pathogenesis of obesity, insulin resistance and diabetes
physiological function
-
the enzyme plays a role in CD3 receptor signal transduction and is is a key component in early T cell activation signaling cascades
physiological function
-
the enzyme regulates TOR signaling and cell growth during Drosophila development
physiological function
-
human enzyme isoforms are able to rescue salivary gland cell size defects in the Drosophila enzyme-deficient mutant
physiological function
-
the enzyme is necessary for maintenance of normal plasma membrane phosphatidylinositol (3,4,5)-trisphosphate levels in DT-40 cells. The enzyme is an acute negative regulator of mammalian target of rapamycin complex 2
physiological function
-
the enzyme is required for the assembly of bipolar spindles. The enzyme and phosphatidylinositol 4,5-bisphosphate may negatively regulate the microtubule depolymerization activity of mitotic centromere-associated kinesin by reducing polo-like kinase 1-mediated phosphorylation of mitotic centromere-associated kinesin
physiological function
-
the enzyme isoforms play potential roles in synaptic transmission
physiological function
-
the enzyme plays a critical role in autophagy in times of energy stress
physiological function
-
the enzyme regulates clathrin-mediated endocytosis of rhodopsin 1 and supports rhodopsin 1 trafficking during pupal metamorphosis
physiological function
-
greater type II alpha PIP kinase activity in the light-adapted rod outer segment membrane results from light-driven translocation of PIPKIIalpha from the rod inner segment to rod outer segment, and subsequent binding to the rod outer segment membrane, thus improving access of the kinase to its lipid substrates. Light-induced tyrosine phosphorylation of rod outer segment membrane proteins regulate the translocation, membrane binding and activation of type II alpha phosphatidylinositol-5-phosphate 4-kinase
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Rameh, L.E.; Tolias, K.F.; Duckworth, B.C.; Cantley, L.C.
A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate
Nature
390
192-196
1997
Homo sapiens
brenda
Itoh, T.; Ijuin, T.; Takenawa, T.
A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase IIgamma) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals
J. Biol. Chem.
273
20292-20299
1998
Rattus norvegicus
brenda
Carricaburu, V.; Lamia, K.A.; Lo, E.; Favereaux, L.; Payrastre, B.; Cantley, L.C.; Rameh, L.E.
The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation
Proc. Natl. Acad. Sci. USA
100
9867-9872
2003
Homo sapiens
brenda
Hinchliffe, K.A.; Irvine, R.F.
Regulation of type II PIP kinase by PKD phosphorylation
Cell. Signal.
18
1906-1913
2006
Sus scrofa
brenda
Clarke, J.H.; Emson, P.C.; Irvine, R.F.
Localization of Phosphatidylinositol phosphate Kinase II gamma in kidney to a membrane trafficking compartment within specialized cells of the nephron
Am. J. Physiol. Renal Physiol.
295
F1422-1430
2008
Homo sapiens (Q8TBX8), Mus musculus (Q91XU3)
brenda
Richardson, J.P.; Wang, M.; Clarke, J.H.; Patel, K.J.; Irvine, R.F.
Genomic tagging of endogenous type IIbeta phosphatidylinositol 5-phosphate 4-kinase in DT40 cells reveals a nuclear localization
Cell. Signal.
19
1309-1314
2007
Gallus gallus, Homo sapiens (P78356)
brenda
Clarke, J.; Irvine, R.
The activity, evolution and association of phosphatidylinositol 5-phosphate 4-kinases
Adv. Biol. Regul.
52
40-45
2012
Mammalia
brenda
Kouchi, Z.; Fujiwara, Y.; Yamaguchi, H.; Nakamura, Y.; Fukami, K.
Phosphatidylinositol 5-phosphate 4-kinase type II beta is required for vitamin D receptor-dependent E-cadherin expression in SW480 cells
Biochem. Biophys. Res. Commun.
408
523-529
2011
Homo sapiens
brenda
Bultsma, Y.; Keune, W.J.; Divecha, N.
PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha
Biochem. J.
430
223-235
2010
Homo sapiens, Rattus norvegicus
brenda
Huang, Z.; Anderson, R.E.; Cao, W.; Wiechmann, A.F.; Rajala, R.V.
Light-induced tyrosine phosphorylation of rod outer segment membrane proteins regulate the translocation, membrane binding and activation of type II alpha phosphatidylinositol-5-phosphate 4-kinase
Neurochem. Res.
36
627-635
2011
Mus musculus, Rattus norvegicus, Rattus norvegicus Sprague-Dawley
brenda
Davis, M.I.; Sasaki, A.T.; Shen, M.; Emerling, B.M.; Thorne, N.; Michael, S.; Pragani, R.; Boxer, M.; Sumita, K.; Takeuchi, K.; Auld, D.S.; Li, Z.; Cantley, L.C.; Simeonov, A.
A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation
PLoS ONE
8
e54127
2013
Homo sapiens
brenda
Bulley, S.J.; Clarke, J.H.; Droubi, A.; Giudici, M.L.; Irvine, R.F.
Exploring phosphatidylinositol 5-phosphate 4-kinase function
Adv. Biol. Regul.
57
193-202
2015
Homo sapiens
brenda
Voss, M.D.; Czechtizky, W.; Li, Z.; Rudolph, C.; Petry, S.; Brummerhop, H.; Langer, T.; Schiffer, A.; Schaefer, H.L.
Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta
Biochem. Biophys. Res. Commun.
449
327-331
2014
Homo sapiens (P78356)
brenda
Clarke, J.H.; Irvine, R.F.
Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization
Biochem. J.
454
49-57
2013
Homo sapiens (P48426), Homo sapiens (P78356), Homo sapiens (Q8TBX8), Homo sapiens
brenda
Clarke, J.H.; Giudici, M.L.; Burke, J.E.; Williams, R.L.; Maloney, D.J.; Marugan, J.; Irvine, R.F.
The function of phosphatidylinositol 5-phosphate 4-kinase gamma (PI5P4Kgamma) explored using a specific inhibitor that targets the PI5P-binding site
Biochem. J.
466
359-367
2015
Mus musculus
brenda
Sinha, R.K.; Bojjireddy, N.; Kulkarni, D.; Ratheesh, A.; Chiplunkar, S.V.; Gude, R.; Subrahmanyam, G.
Type II phosphatidylinositol 4-kinase beta is an integral signaling component of early T cell activation mechanisms
Biochimie
95
1560-1566
2013
Homo sapiens
brenda
Boura, E.; Nencka, R.
Phosphatidylinositol 4-kinases: Function, structure, and inhibition
Exp. Cell Res.
337
136-145
2015
Homo sapiens
brenda
Elouarrat, D.; van der Velden, Y.U.; Jones, D.R.; Moolenaar, W.H.; Divecha, N.; Haramis, A.P.
Role of phosphatidylinositol 5-phosphate 4-kinase ? in zebrafish development
Int. J. Biochem. Cell Biol.
45
1293-1301
2013
Danio rerio
brenda
Xu, J.X.; Si, M.; Zhang, H.R.; Chen, X.J.; Zhang, X.D.; Wang, C.; Du, X.N.; Zhang, H.L.
Phosphoinositide kinases play key roles in norepinephrine- and angiotensin II-induced increase in phosphatidylinositol 4,5-bisphosphate and modulation of cardiac function
J. Biol. Chem.
289
6941-6948
2014
Rattus norvegicus
brenda
Bojjireddy, N.; Sinha, R.K.; Subrahmanyam, G.
Type II phosphatidylinositol 4-kinases interact with FcepsilonRIgamma subunit in RBL-2H3 cells
Mol. Cell. Biochem.
390
197-203
2014
Homo sapiens
brenda
Tang, Y.; Zhao, C.Y.; Tan, S.T.; Xue, H.W.
Arabidopsis type II phosphatidylinositol 4-kinase PI4Kgamma5 regulates auxin biosynthesis and leaf margin development through interacting with membrane-bound transcription factor ANAC078
PLoS Genet.
12
e1006252
2016
Arabidopsis thaliana
brenda
Gupta, A.; Toscano, S.; Trivedi, D.; Jones, D.R.; Mathre, S.; Clarke, J.H.; Divecha, N.; Raghu, P.
Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) regulates TOR signaling and cell growth during Drosophila development
Proc. Natl. Acad. Sci. USA
110
5963-5968
2013
Drosophila melanogaster
brenda
Manz, T.D.; Sivakumaren, S.C.; Yasgar, A.; Hall, M.D.; Davis, M.I.; Seo, H.S.; Card, J.D.; Ficarro, S.B.; Shim, H.; Marto, J.A.; Dhe-Paganon, S.; Sasaki, A.T.; Boxer, M.B.; Simeonov, A.; Cantley, L.C.; Shen, M.; Zhang, T.; Ferguson, F.M.; Gray, N.S.
Structure-activity relationship study of covalent pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors
ACS Med. Chem. Lett.
11
346-352
2020
Homo sapiens
brenda
Giudici, M.; Clarke, J.; Irvine, R.
Phosphatidylinositol 5-phosphate 4-kinase gamma (PI5P4Kgamma), a lipid signalling enigma
Adv. Biol. Regul.
61
47-50
2016
Homo sapiens
brenda
Droubi, A.; Bulley, S.; Clarke, J.; Irvine, R.
Nuclear localizations of phosphatidylinositol 5-phosphate 4-kinases alpha and beta are dynamic and independently regulated during starvation-induced stress
Biochem. J.
473
2155-2163
2016
Gallus gallus
brenda
Mathre, S.; Reddy, K.B.; Ramya, V.; Krishnan, H.; Ghosh, A.; Raghu, P.
Functional analysis of the biochemical activity of mammalian phosphatidylinositol 5 phosphate 4-kinase enzymes
Biosci. Rep.
39
BSR20182210
2019
Homo sapiens
brenda
Lin, T.C.; Kuo, H.H.; Wu, Y.C.; Pan, T.S.; Yih, L.H.
Phosphatidylinositol-5-phosphate 4-kinase gamma accumulates at the spindle pole and prevents microtubule depolymerization
Cell Div.
14
9-9
2019
Homo sapiens
brenda
Sharma, S.; Mathre, S.; Ramya, V.; Shinde, D.; Raghu, P.
Phosphatidylinositol 5 phosphate 4-kinase regulates plasma-membrane PIP3 turnover and insulin signaling
Cell Rep.
27
1979-1990
2019
Drosophila melanogaster
brenda
Kamalesh, K.; Trivedi, D.; Toscano, S.; Sharma, S.; Kolay, S.; Raghu, P.
Phosphatidylinositol 5-phosphate 4-kinase regulates early endosomal dynamics during clathrin-mediated endocytosis
J. Cell Sci.
130
2119-2133
2017
Drosophila melanogaster
brenda
Noch, E.K.; Yim, I.; Milner, T.A.; Cantley, L.C.
Distribution and localization of phosphatidylinositol 5-phosphate, 4-kinase alpha and beta in the brain
J. Comp. Neurol.
529
434-449
2020
Mus musculus
brenda
Manz, T.D.; Sivakumaren, S.C.; Ferguson, F.M.; Zhang, T.; Yasgar, A.; Seo, H.S.; Ficarro, S.B.; Card, J.D.; Shim, H.; Miduturu, C.V.; Simeonov, A.; Shen, M.; Marto, J.A.; Dhe-Paganon, S.; Hall, M.D.; Cantley, L.C.; Gray, N.S.
Discovery and structure-activity relationship study of (Z)-5-methylenethiazolidin-4-one derivatives as potent and selective pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors
J. Med. Chem.
63
4880-4895
2020
Homo sapiens
brenda
Davis, M.; Sasaki, A.; Simeonov, A.
Method for assaying the lipid kinase phosphatidylinositol-5-phosphate 4-kinase alpha in quantitative high-throughput screening (qHTS) bioluminescent format
Methods Mol. Biol.
1376
1-9
2016
Homo sapiens (P48426)
brenda
Lundquist, M.; Goncalves, M.; Loughran, R.; Possik, E.; Vijayaraghavan, T.; Yang, A.; Pauli, C.; Ravi, A.; Verma, A.; Yang, Z.; Johnson, J.; Wong, J.; Ma, Y.; Hwang, K.; Weinkove, D.; Divecha, N.; Asara, J.; Elemento, O.; Rubin, M.; Kimmelman, A.; Pause, A.
Phosphatidylinositol-5-phosphate 4-kinases regulate cellular lipid metabolism by facilitating autophagy
Mol. Cell.
70
531-544
2018
Mus musculus
brenda
Bulley, S.J.; Droubi, A.; Clarke, J.H.; Anderson, K.E.; Stephens, L.R.; Hawkins, P.T.; Irvine, R.F.
In B cells, phosphatidylinositol 5-phosphate 4-kinase-alpha synthesizes PI(4,5)P2 to impact mTORC2 and Akt signaling
Proc. Natl. Acad. Sci. USA
113
10571-10576
2016
Gallus gallus
brenda